Quantcast
Channel: Health VC Feed » Flagship Ventures
Browsing latest articles
Browse All 20 View Live

Image may be NSFW.
Clik here to view.

What Was Hyped, and What Fell Out of Favor, This Year in Biotech

Luke Timmerman Every year, Science magazine profiles its “Breakthrough of the Year.” People get excited. But what many readers don’t fully appreciate is that these discoveries—at least in …

View Article



Image may be NSFW.
Clik here to view.

Eleven Prices IPO Below Projected Range, Grabs $50M

Ben Fidler Eleven Biotherapeutics wants to prove that a drug it’s developing can go toe to toe with Allergan’s big-selling dry eye disease drug, Restasis. Wall Street, however, was tepid …

View Article

Image may be NSFW.
Clik here to view.

Concert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share

Ben Fidler What’s it worth to add a little deuterium to drugs to boost their abilities? In Wall Street’s eyes, about $14 per share. Lexington, MA-based Concert Pharmaceuticals will debut …

View Article

Image may be NSFW.
Clik here to view.

What’s Hot in Boston Biotech: Here’s the Agenda for April 16

Ben Fidler There are plenty of reasons Wall Street is jittery that a biotech bubble is about to pop. But this bull market formed for a reason: innovative new science …

View Article

Agios’s Blood Cancer Drug Shines in First Clinical Test

Ben Fidler When David Schenkein left Genentech to lead Agios Pharmaceuticals in 2009, part of the draw was the fact that the Cambridge, MA-based startup was positioning itself as a …

View Article


7 Takeaways From “What’s Hot in Boston Biotech”

Ben Fidler Sometimes it takes a contrarian viewpoint, and a little guts, to get a scientific idea off the ground. Other times an idea can be so enthralling that venture …

View Article

Image may be NSFW.
Clik here to view.

Get a Window on the Innovation Future at Boston 2034 on June 10

Robert Buderi It’s gotten to be an easy rant—chastising entrepreneurs for not thinking big enough. But that’s plain wrong, especially in the Boston area. New England visionaries have long been …

View Article

Moderna, Changing Its Identity, Plots Army of mRNA Spinouts

Ben Fidler Kendall Square has found its newest biotech incubator. Moderna Therapeutics just had no idea it’d be the one running it. Moderna, the high-flying, privately held startup that raised …

View Article


One More Thought From Boston 2034: Tech + Biotech + Cleantech = ?

Gregory T. Huang When we assembled some of the top business leaders and thinkers across New England for Boston 2034 last week, I noticed a high-level theme: we were trying …

View Article


Image may be NSFW.
Clik here to view.

The Second Xconomy Boston Healthcare Summit: Request An Invitation

Robert Buderi A lot has happened in healthcare over the past year. For starters, Healthcare.gov, the federal website for buying insurance under the Affordable Care Act, has gone up, …

View Article

Image may be NSFW.
Clik here to view.

With Crossover Cash, Seres Health Aims For Big Microbiome Milestones

Alex Lash Seres Health of Cambridge, MA, announced two big steps Tuesday. First, it says it has raised $48 million in a Series C round from public investors, which is (Read more...)

View Article

Image may be NSFW.
Clik here to view.

Phytonix Turns Photosynthetic Bacteria Into Tiny Chemical Factories

Frank Vinluan Ambitions for biologically sourced fuels bump up against the reality that making chemicals and fuels from organic material is still generally more expensive. One company is hoping to...

View Article

Image may be NSFW.
Clik here to view.

With Massive Venture Round, Moderna Has $450M Reasons to Stay Private

Ben Fidler Investment dollars have been pouring into private and public biotechs, but nothing can quite match Moderna Therapeutics. Cambridge, MA-based Moderna says it has raised a $450 million...

View Article


Image may be NSFW.
Clik here to view.

With $21M, Retooled Blend Whips up Mini-Smart Bombs For Cancer

Ben Fidler Sometimes in biotech, you go in with one plan, and an unexpected discovery changes everything. That’s the case with Blend Therapeutics, which has morphed into a company trying (Read more...)

View Article

Image may be NSFW.
Clik here to view.

J.P. Morgan 2015: Notes, Thoughts, And Conversations From the Vortex

Alex Lash The word “story” gets ill treatment at events like the J.P. Morgan Healthcare Conference. It often means an elevator pitch from a harried CEO to a distracted (Read more...)

View Article

Browsing latest articles
Browse All 20 View Live




Latest Images